

North Central Cancer Treatment Group

N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 yrs) with Good Performance Status (PS < 2)

Status Change – October 30, 2009

NOTICE OF STATUS CHANGE

This study is temporarily closed to accrual to review and evaluate toxicity per study design effective today, October 30, 2009.

Patient entry will not be permitted after October 30, 2009.

Patients currently on study should be followed according to the protocol.

Please retain this notice with the protocol.